5 recruiting, 4 completed, 3 active not recruiting, 3 terminated. 8 Phase 1, 5 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 3, Active not recruiting 2, Terminated 2, Recruiting 1 |
| Phase 2 | 5 | Recruiting 3, Completed 1, Terminated 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
Follow Advanced Breast Carcinoma: new trials by email Literature Review of Advanced Breast Carcinoma trials Research Report on Advanced Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Living Well With Advanced Breast Cancer Non-Interventional Study - Advanced Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-01-13 | 2026-03-19 | |
| Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype Trastuzumab deruxtecan (T-DXd, DS-8201a), CDK4/6i plus ET - Advanced Breast Cancer, Advanced Breast Carcinoma | Phase 2 | Recruiting | MedSIR | 200 | 2025-06-30 | 2026-07-30 |
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment - Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 220 | 2023-08-23 | 2026-04-20 |
| Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer Advanced Breast Carcinoma | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 600 | 2023-02-01 | 2024-04-24 | |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Cisplatin, Elimusertib, Gemcitabine Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2021-08-25 | 2026-07-31 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-09-04 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NUV-422 - Glioma, Glioma, Malignant | Phase 1 | Terminated | Nuvation Bio Inc. | 74 | 2020-12-08 | 2023-07-14 |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer Cediranib, Ceralasertib, Olaparib - Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 60 | 2020-07-28 | 2026-09-14 |
| Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer Alpelisib, Enzalutamide - Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 18 | 2019-06-07 | 2024-10-10 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 23 | 2018-09-24 | 2026-04-29 |
| Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis - Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma | Active not recruiting | Mayo Clinic | 68 | 2017-11-13 | 2026-06-09 | |
| TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer Anastrozole, Denifanstat, Exemestane - Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma | Phase 2 | Completed | Mayo Clinic | 17 | 2017-08-03 | 2026-10-09 |
| Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer Laboratory Biomarker Analysis, Onalespib, Paclitaxel - Advanced Breast Carcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 31 | 2016-01-15 | 2022-11-04 |
| Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer ONT-10, Varlilumab combination - Advanced Breast Carcinoma, Advanced Ovarian Carcinoma | Phase 1 | Completed | Cascadian Therapeutics Inc. | 22 | 2014-11-01 | 2018-05-17 |
Breast Neoplasms (10) · Ovarian Neoplasms (4) · Prostatic Neoplasms (4) · Triple Negative Breast Neoplasms (4) · Endometrial Neoplasms (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Carcinosarcoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1) · Glioma (1)
Neoplasms (13) · Neoplasms by Site (12) · Breast Diseases (11) · Skin Diseases (11) · Skin and Connective Tissue Diseases (11) · Genital Diseases (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7) · Male Urogenital Diseases (6) · Neoplasms by Histologic Type (6) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases, Female (5) · Genital Diseases, Male (5) · Genital Neoplasms, Female (5)
Biopsy (5) · Taxes (4) · Letrozole (3) · Paclitaxel (3) · Specimen Handling (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2) · Alpelisib (2) · Anastrozole (2) · Disulfides (2) · Fulvestrant (2) · Gemcitabine (2) · Magnetic Resonance Spectroscopy (2) · Ogivri (2) · Ontruzant (2)
National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (3) · Mayo Clinic (3) · OHSU Knight Cancer Institute (2) · Cascadian Therapeutics Inc. (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · MedSIR (1) · Nuvation Bio Inc. (1) · Ohio State University Comprehensive Cancer Center (1)
United States (14) · Italy (2) · Austria (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Netherlands (1) · Poland (1) · Portugal (1) · Spain (1) · United Kingdom (1)
Alessandra Fabi, MD (1) · Alison M Schram (1) · Apostolia M Tsimberidou (1) · Ashley P Davenport, MD (1) · Banu Arun (1) · Charles D Lopez, MD, PhD (1) · Ciara O'Sullivan, M.B., B.Ch. (1) · Kanwal P Raghav (1) · Lara Davis (1) · Mamta Parikh (1) · Meghan Karuturi (1) · Robert Wesolowski (1) · Roxana S. Dronca, MD (1) · Tufia C. Haddad, M.D. (1)
PMID 36351402, PMID 38152697, PMID 40939237
P50CA168504 (1), UM1CA186688 (1), UM1CA186691 (1), UM1CA186712 (1), UM1CA186717 (1)